back to
back to

Program: Saturday (26.10.2024)

08:30 – 11:00

Room: Marsilius Saal

Separate registration required Workshop Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma

08:30 – 11:00

Room: Großer Saal

Educational EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas”

  • Igor Aurer
  • Bastian von Tresckow
  • 08:30–08:33

    Introduction

  • 08:33–08:55

    Molecular and microenvironmental vulnerabilities of B-cell lymphomas

    • Sirpa Leppä
  • 08:55–09:17

    Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma?

    • Marie Jose Kersten
  • 09:17–09:39

    Who needs bispecific antibodies as first-line treatment in aggressive lymphoma?

    • Catherine Thieblemont
  • 09:39–10:01

    How to implement novel ADCs in the first-line treatment of lymphoma

    • Pier Luigi Zinzani
  • 10:01–10:23

    Perspectives of small molecule based first-line therapy of LBCL

    • Theodoros Vasilakopoulos
  • 10:23–10:45

    Treatment and Trial Landscape for Malignant Lymphoma in China

    • Yuqin Song

11:30 – 13:00

Room: Großer Saal

Scientific Session Limited Stages

  • Marc André
  • Lena Specht
  • 11:30–11:50

    IIntro: Treatment concepts in early-stage HL

    • Marc André
  • 11:50–12:10

    Viewpoint: Systemic Therapy only in the future?

    • Ranjana Advani
  • 12:10–12:30

    Viewpoint: CMT (is it there to stay?)

    • Joachim Yahalom
  • 12:30–12:40

    Factors driving treatment intensity in the whole cohort of patients with early-stage favorable (I-IIA), nonbulky Hodgkin Lymphoma enrolled in the RAFTING trial (NCT 04866654).

    • Andrea Gallamini
  • 12:40–12:50

    Nodular lymphocyte predominant Hodgkin lymphoma in the Nordic countries – characteristics, treatment and survival

    • Ingrid Glimelius
  • 12:50–13:00

    Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume During Anti-PD1-Based First-Line HL Treatment in The GHSG Phase II NIVAHL Trial

    • Wouter Plattel

13:15 – 14:45

Room: Großer Saal

Satellite Symposium (by BeiGene Switzerland GmbH) The evolving role of BTKis in the treatment of B-cell lymphomas

  • Christian Buske
  • 13:15–13:20

    Welcome and Introduction

    • Christian Buske
  • 13:20–13:40

    BTKis in indolent lymphomas (FL, MZL)

    • Catherine Thieblemont
  • 13:40–13:58

    BTKis in WM

    • Christian Buske
  • 13:58–14:14

    BTKis in MCL

    • David Lewis
  • 14:14–14:29

    Future developments (CDAC, BCL2, anti PD1/PDL1)

    • Anna Maria Frustaci
  • 14:29–14:44

    Panel discussion, audience Q&A

  • 14:44–14:45

    Closure and farewell

    • Christian Buske

15:15 – 17:00

Room: Großer Saal

Main Program Opening and Award Ceremony

  • 15:15–15:30

    Welcome Address

    • Peter Borchmann
    • Volker Diehl
  • 15:30–16:00

    Award Ceremony

    • Peter Borchmann
    • Sven Borchmann
    • Paul J. Bröckelmann
    • Dennis Eichenauer
  • 16:00–17:00

    Keynote Lecture

    • Linda Partridge

17:15 – 20:00

Room: Foyer (First Floor)

Main Program Poster Session & Welcome Reception

  • All poster presenters are required to be present at their poster boards from 17:15 to 19:00

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.